<DOC>
	<DOCNO>NCT02972632</DOCNO>
	<brief_summary>The purpose study determine effectiveness treatment vortioxetine participant goal achievement change antidepressant medication treatment major depressive disorder ( MDD ) .</brief_summary>
	<brief_title>Goal Achievement After Change Vortioxetine Adults With Major Depressive Disorder</brief_title>
	<detailed_description>The drug test study call Vortioxetine . Vortioxetine test treat depression people major depressive disorder . This study look effectiveness treatment vortioxetine participant 's goal achievement treatment major depressive disorder . The study enroll approximately 120 patient . Participants receive : • Vortioxetine 10 20 mg All participant ask take one tablet time day throughout study . The participant receive start dose 10 mg . The dose may up-titrated 20 mg . The dose may decrease 5 mg base participant 's response tolerability high dose judge Investigator . This multi-center trial conduct Unites States . The overall time participate study 19 week . Participants make multiple visit clinic , contact telephone 4 week last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>1 . Is suffer Major Depressive Disorder ( MDD ) primary psychiatric diagnosis . 2 . Has currently treat approve antidepressant ( monotherapy ) 6 week longer adequate therapeutic dose . Participants currently antidepressant Screening discontinue manner consistent label recommendation conventional medical practice . 3 . The antidepressant treatment must ongoing time Screening , discontinue within 6 week prior Screening . 4 . Is consider appropriate change antidepressant medication base Investigator judgment collaboration participant . 5 . Has score Patient Health Questionnaire ( PHQ9 ) ≥5 Clinical Global Impression Scale Severity ( CGIS ≥4 ) . 1 . Has discontinue prior antidepressant treatment great 6 week Screening . 2 . Is consider imminent risk hospitalization due severe depression opinion investigator . Recent hospitalization due MDD within 3 month prior Screening exclusionary also . 3 . Has significant risk suicide accord Investigator 's clinical judgment make actual suicide attempt previous 6 month prior Screening score `` yes '' item 4 5 Suicidal Ideation section Columbia Suicide Severity Rating Scale ( CSSRS ) . 4 . Is consider treatment resistant , define participant MDD respond 2 separate different antidepressant monotherapy trial adequate dose duration ( 6 week longer ) current episode . History respond combination augmentation therapy previous major depressive episode ( MDEs ) also consider evidence treatment resistant depression . 5 . Has 1 follow : 1 . Current history : manic hypomanic episode , schizophrenia psychotic disorder , include schizoaffective disorder , major depression psychotic feature , bipolar depression psychotic feature , obsessive compulsive disorder , mental retardation , organic mental disorder , mental disorder due general medical condition define Diagnostic Statistical Manual Mental Disorders ( DSM5 ) determine investigator . 2 . Current diagnosis history alcohol substance abuse dependence ( exclude nicotine caffeine ) . The participant must negative urine drug screen ( UDS ) Screening Baseline , include benzodiazepine opiate ( include oxycodone ) prescription . 3 . Presence history clinically significant neurological disorder ( include epilepsy ) determine investigator . 4 . Neurodegenerative disorder ( Alzheimer disease , Parkinson disease , multiple sclerosis , Huntington disease , etc ) . 6 . Has know history acute narrowangle glaucoma risk acute narrowangle glaucoma . 7 . Has know unstable thyroid disorder thyroidstimulating hormone value outside normal range base medical history deem clinically significant investigator . 8 . Has active hepatitis B know history hepatitis C virus . 9 . Has know history human immunodeficiency virus infection . 10 . Has history gastric bypass . 11 . Has previously currently participate study another vortioxetine LuAA21004 study . 12 . Is receive start receive formal cognitive behavioral therapy , systematic psychotherapy within 30 day screen plan initiate therapy study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>